DDInter944 DDInter298
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) MT2A
MT2A {u} (Gene) is bound by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may lead to a major life threatening interaction when taken with {v} Zidovudine
Zidovudine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may lead to a major life threatening interaction when taken with {v} Zidovudine
Zidovudine {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Carboplatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds SLC31A1 (Gene) and Bortezomib (Compound) upregulates SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Carboplatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) downregulates MT2A (Gene) and MT2A (Gene) is bound by Carboplatin (Compound)
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Carboplatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)